Amsterdam, The Netherlands - June 4, 2007 - Amsterdam Molecular Therapeutics (AMT), a leader in the field of human gene therapy, today announced that its lead product, AMT 011, has received Orphan Drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of Lipoprotein Lipase (LPL) Deficiency.
